MiR-17-92 Cluster-Enriched Exosomes Derived from Human Bone Marrow Mesenchymal Stromal Cells Improve Tissue and...

Area of Science:

• Neuroscience
• Regenerative Medicine
• Cell Biology

Background:

• Exosomes mediate intercellular communication via miRNA delivery.
• Mesenchymal stromal cell (MSC)-derived exosomes show promise in treating experimental traumatic brain injury (TBI).
• Specific miRNA enrichment in exosomes may enhance therapeutic efficacy.

Purpose of the Study:

• To evaluate the efficacy of miR-17-92 cluster-enriched exosomes (Exo-17-92) from human bone marrow MSCs in treating TBI.
• To compare the therapeutic effects of Exo-17-92 with control exosomes (Exo-empty) and vehicle treatment.
• To investigate the impact on tissue recovery, neurological function, and underlying biological mechanisms.

Main Methods:

• Adult male rats with unilateral moderate cortical contusion TBI received intravenous injections of Exo-17-92, Exo-empty, or vehicle.
• Neurological function was assessed weekly for five weeks using functional tests and the Morris water maze.
• Brain tissues were analyzed post-mortem for lesion volume, cell loss, angiogenesis, neurogenesis, and neuroinflammation.

Main Results:

• Both Exo-17-92 and Exo-empty treatments improved sensorimotor and cognitive function, reduced neuroinflammation and cell loss, and promoted angiogenesis and neurogenesis compared to vehicle.
• Exo-17-92 demonstrated significantly superior therapeutic effects over Exo-empty in functional recovery, neuroinflammation reduction, and neurogenesis promotion.
• Neither exosome treatment altered the lesion volume post-TBI.

Conclusions:

• Exosomes enriched with the miR-17-92 cluster exhibit enhanced therapeutic potential for TBI recovery.
• This enhancement is likely due to reduced neuroinflammation and increased endogenous angiogenesis and neurogenesis.
• Engineering exosomes with specific miRNAs represents a promising novel therapeutic strategy for TBI management.